Jump to content
Barree

MORE LUTETIUM CLINICAL TRIALS ON THE WAY

Recommended Posts

Barree

The trial is titled "Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Strategies for PSMA Negative Disease".

These clinical trials are headed by Prof. Michael Hofman and A/Prof. Arun Azad of Peter Mac. Recruiting is expected start early next year.Details of these trials will follow later this year. In essence, Lutetium will be given earlier in the piece, Lutetium will in special circumstances be given prior to robotic surgery, Research will commence into CAR T cell  treatment for prostate cancer which is not PSMA avid and cannot currently be treated using Lutetium.

A dedicated team of specialist Doctors,Scientists and Clinical Researchers at Peter Mac have just successfully applied to the Movember/ Cancer Australia Prostate Cancer Research Alliance for funding of these new Lutetium trials. (see details by clicking this link to the Peter Mac site) http://tinyurl.com/y36xuwqg

This is a world-class proposal from a world-class multi-institutional Australian team. Movember and Cancer Australia will jointly provide $4M in funding to the Alliance. In addition generous financial support for these trials totalling $1.4M will also be provided by Peter Mac Foundation, University of Melbourne, Victoria Cancer Agency, Monash University, Epworth/E.J Whitten Foundation, Peter Mac Research Division. This funding will be used solely for prostate cancer research

The grant interview team for this project consisted of Prof. Michael Hofman, A/Prof. Arun Azad, A/Prof. Declan Murphy and yours truly as a consumer representative.

Hopefully these trials will provide a quantum leap forward for prostate cancer treatment.

Share this post


Link to post
Share on other sites
Charles (Chuck) Maack

What wonderful news for patients throughout the world.  A world-class effort by Australia and the many parties involved to make it happen!.  Congratulations, Australia, and we should all pray that events will move ahead rapidly.

Share this post


Link to post
Share on other sites
PeterA

 

Well done Barry!

PeterA

Share this post


Link to post
Share on other sites
Barree

NEW TRIAL LUTETIUM / OLAPARIB   JUST ANNOUNCED - NOW RECRUTING AT PETER MAC.  For members with metastatic disease that have had docetaxel and have had progressed after having been on either Enza (Ezalutamide) Or Abi(Arbiraterone). Other selection criteria applies relating to Scans & PSMA expression. This looks like a great opportunity for those looking to get on a Lutetium/Parp trial. You should be able to fly in and out for this one. 4 Treatments -6 Weeks apart.9see details  in attachment)If this is looks to be of of interest email me for contact details. Barree.

LUTETIUM-PARP TRIAL2.jpg

Share this post


Link to post
Share on other sites
ardee

Very interesting - I am assuming participants do not have to be BRCA+.

 

We have a couple of men who are BRCA2+ and have been considering Lu177 PSMA - although both are already on olaparib, and one is sadly now too far gone with brain mets. He was admitted to a Lu trial but then withdrew.

 

I am very curious as to the combination - does anyone know the hypothesis behind combining Lu177 with a PARP-I?? 

 

Onward & upwards, rd

 

PS AnCan is hosting a webinar tomorrow (Tuesday for you, I think) on The Language of Cancer https://ancan.org/event/the-language-of-cancer/ - please join us to provide a littel Aussie flavor. You can send questions to rd@ancan.org, or join online and use the Chat window. Free and drop-in - no reservation required. 

 

 

Share this post


Link to post
Share on other sites
GrahamW

Somewhere down in the fine print among the exclusions for the LuPARP trial:

  • Any prior exposure to 177Lu-PSMA, cabazitaxel, platinums, PARP inhibitors, mitoxantrone or cyclophosphamide.

The last two rule me out, as I had 4 cycles of these chemo drugs straight after surgery in 2006.

Share this post


Link to post
Share on other sites
Barree

PRINCE trial combining Lu-177 PSMA-617 and immunotherapy Keytruda (pembroluzimab) now recruiting at Peter Mac in Melbourne for patients with metastatic Castration Resistant Prostate Cancer (mCRPC).

Keytruda given 3 weekly up to 35 times and up to 4 cycles at  6-weekly intervals of 177Lu-PSMA treatments.

Click this link to get full trial details: https://clinicaltrials.gov/ct2/show/NCT03658447

 If you require any further information please email me or Contact Peter Mac direct (03) 8559 5000

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...